France-based Median Technologies is reporting revenue increases for the third quarter of the 2024 fiscal year, which ended on 30 September.
The company reported a quarterly revenue of €6.2 million, second highest ever for Median, up 10.7% versus the same quarter in 2023. Additionally, Median reported a total year-to-date revenue of €17.1 million.
The company highlighted that it is "on track" to file U.S. and European marketing authorization for its eyonis lung cancer screening tool in the first half of 2025. Eyonis is an AI-powered diagnostic device that uses machine learning to help analyze low-dose CT imaging data to diagnose lung cancer at the earliest stages.
Median reported €10.3 million in external costs as of June 30 compared with €8.9 million a year before. This reflects an increase in Median’s IT infrastructure costs to support eyonis, the company added.
